Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neurotech International ( (AU:NTI) ) has issued an announcement.
Neurotech International Limited has announced a change in its registered office and principal place of business to a new address in Melbourne, effective immediately. This move is part of the company’s ongoing operational adjustments, potentially enhancing its strategic positioning within the biopharmaceutical industry focused on pediatric neurological disorders.
More about Neurotech International
Neurotech International Limited is a clinical-stage biopharmaceutical company focused on developing treatments for pediatric neurological disorders. The company is primarily working on NTI164, an oral cannabinoid drug therapy, and has conducted successful clinical trials in Autism Spectrum Disorder (ASD), PANDAS/PANS, and Rett Syndrome. Neurotech is also preparing for a clinical trial in spastic cerebral palsy.
Average Trading Volume: 622,495
Technical Sentiment Signal: Sell
Current Market Cap: A$19.94M
Learn more about NTI stock on TipRanks’ Stock Analysis page.